# Phase 2 Study to Evaluate the Microbiology and Safety of C16G2 Administered to Adult and Adolescent Dental Subjects

> **NCT02594254** · PHASE2 · COMPLETED · sponsor: **Armata Pharmaceuticals, Inc.** · enrollment: 135 (actual)

## Conditions studied

- Dental Caries

## Interventions

- **DRUG:** C16G2 Gel
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02594254
- **Lead sponsor:** Armata Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11
- **Primary completion:** 2016-06
- **Final completion:** 2016-09
- **Target enrollment:** 135 (ACTUAL)
- **Last updated:** 2019-08-01

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02594254

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02594254, "Phase 2 Study to Evaluate the Microbiology and Safety of C16G2 Administered to Adult and Adolescent Dental Subjects". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02594254. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*